Adel Mesfer S AlghamdiHera General Hospital, KSA
Title: A case report of a pregnant woman with type 2 diabetes mellitus using dulaglutide during the first trimester of pregnancy
Among women of childbearing age, Type 2 Diabetes Mellitus (T2DM) is becoming more prevalent, increasing the likelihood of abortion, congenital anomalies, and neonatal death. Dulaglutide has not been adequately studied to determine if it causes birth defects or miscarriages during pregnancy. According to animal studies, the foetus is at risk from the use of dulaglutide during pregnancy. We report the case of a 39-year-old woman with T2DM who used dulaglutide (1.5 mg/week) along with glargine and as part before conception. During the third month of pregnancy, she was seen in the clinic for the first time during which dulaglutide was stopped and basal-bolus insulin therapy was retained with dosing titration. The newborn was a male with a normal birth weight for his gestational age. Dulaglutide did not affect development. No minor or major malformations were noted in the foetus except for mild bilateral renal pyelectasis. Moreover, no maternal or foetal complications were observed. It is not possible to ascertain the safety of glucagon-like peptide-1 receptor agonists in pregnancy, despite the normal outcome in the present pregnancy; however, the data described here may be of value in further considering this issue.
Adel Mesfer S Alghamdi is a consultant diabetologist at the Hera General Hospital, Makkah in Saudi Arabia. He is currently working full-time inpatient and outpatient diabetic patients care with
T1DM, T2DM, pregnant with T1DM or T2DM, GDM, & Insulin Pump Clinics. He is a trainer in Diabetes Fellowship Program by Saudi Commission for Health Speciality (SCFHS)